Blog

CNS/Pain

Evaluation of Anti-migraine Therapeutics: Utilizing the Cap-induced Dermal Blood Flow (CIDBF) Rat Model

Our novel diagnostic tool, Capsaicin-induced Dermal Blood Flow (CIDBF), uses the TRPV1 receptor agonist, capsaicin, to measure therapeutic potential of drugs for migraines.

Inflammation/Allergy

CDAHFD Diet-Induced NASH Model in Humanized Liver Chimeric Mice

PDS offers efficacy testing using humanized liver chimeric mice, PXB-mice, in the CDHFD-induced NASH model. The resulting model accurately replicates the key features of human NASH, including liver steatosis, inflammation and fibrosis.

Inflammatory Bowel Disease (IBD) Models

Human inflammatory bowel disease (IBD) is a chronic inflammatory condition comprising two major disorders, Crohn’s disease (CD) and ulcerative colitis (UC). The fundamental symptoms of IBD are diarrhea, abdominal pain, rectal bleeding, and weight loss. Both diseases affect men and women equally and may occur in adolescents as well as in adults...

In Vivo PK

Determine the Pharmacokinetics (PK) and Organ Distributions of Your Drug Candidates

Pharmacokinetics (PK) is often referred to as “what the body does to a drug,” as the study of a drug’s absorption, distribution, metabolism, and excretion (ADME). Alternatively, pharmacodynamics (PD) describes “what a drug does to the body,” by involving receptor binding, chemical interactions, and post-receptor effects.

Metabolic

E. Coli Infected UTI, STZ-Induced Diabetic Model

Diabetes mellitus is an augmenting problem with huge social, health, and economic consequences globally. According to International Diabetes Federation (IDF), the global diabetes prevalence in 2021 is estimated to be 10% (537 million people), rising to 11% (643 million) by 2030 and 12.5% (783 million) by 2045.

Oncology

Developing Orthotopic Brain Cancer Models Bring New Hope for Glioblastoma Treatment

Our scientists at Pharmacology Development Service (PDS) have developed an important oncology research tool involving introducing human glioblastoma cells directly into the brain of mice, creating an approach that closely mimics the tumor's growth, microenvironment, and interaction with surrounding brain tissue in patients.

These brain orthotopic models offer a sophisticated platform for deciphering the intricacies of tumor biology, and a dynamic tool for testing the ability of therapeutic agents to cross the blood-brain barrier. Ultimately, the PDS approach offers a pathway to developing more effective and targeted treatments for glioblastoma.

In Vivo Oncology Models for Drug Discovery

Pharmacology Discovery Services (PDS), a partner lab of Eurofins Discovery, provides a comprehensive collection of validated in vivo oncology models to present key decision-making information for allowing test agents to move forward. Our services provide the data clients need to advance their preclinical development programs in a manner that is timely, flexible, and cost-effective. Each model can be customized to meet specific pharmacology needs.